etec vaccine

Vaccineexperimental

Clinical trial activity

7 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Mar 10, 2014 (NCT02052934)

Timeline

2010s

  1. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2025

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • etec strain b7a
  • etec vaccine
  • recombinant double mutant heat-labile toxin lt(r192g/l211a) (dmlt) oral entertoxigenic escherichia coli (etec) vaccine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06692907Phase 2Jan 13, 2025National Institute of Allergy and Infectious Diseases (NIAID)
NCT03548064Phase 1Oct 11, 2018National Institute of Allergy and Infectious Diseases (NIAID)
NCT03404674Phase 1Jan 16, 2018PATH, United States Army, United States Navy
NCT02531685Phase 1Jun 2, 2016National Institute of Allergy and Infectious Diseases (NIAID)
NCT02773446N/AApr 1, 2016Department of Defense, Johns Hopkins University, PATH, United States Navy
NCT02531802Phase 1/Phase 2 (Phase 2)Oct 1, 2015International Center for Diarrheal Disease Research, PATH, Scandinavian Biopharma AB
NCT02052934Phase 1Mar 10, 2014National Institute of Allergy and Infectious Diseases (NIAID)
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Institute of Allergy and Infectious Diseases (NIAID)Government4422014
PATHAcademic/Hospital3232015
United States NavyGovernment2022016
Department of DefenseGovernment1012016
International Center for Diarrheal Disease ResearchAcademic/Hospital1012015
Johns Hopkins UniversityAcademic/Hospital1112016
Scandinavian Biopharma ABFor profit1012015
United States ArmyGovernment1012018
8 organizations
Page 1 / 1